Omeros (OMER) Income from Continuing Operations (2010 - 2026)
Omeros recorded quarterly Income from Continuing Operations of 51249000.0 in Q1 2026, up 239.68% quarter-over-quarter from 36690000.0 in Q4 2025, and up 236.43% year-over-year from 15233295.76 in Q1 2025.
Omeros' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 51249000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 236.43% year-over-year to 51249000.0; the TTM figure through Mar 2026 stood at 28990000.0 (up 83.34% YoY), while the FY2025 annual figure was 4808000.0, up 97.37% from the prior year.
- Income from Continuing Operations came in at 51249000.0 for Q1 2026 at Omeros, up from 36690000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 51249000.0 in Q1 2026 to a low of 65125000.0 in Q2 2024.
- A 5-year average of 35762294.12 and a median of 39683000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 141.34% in 2022 and surged 236.43% in 2026, its largest moves.
- Omeros' Income from Continuing Operations stood at 46048000.0 in 2022, then increased by 5.75% to 43399000.0 in 2023, then grew by 21.07% to 34255000.0 in 2024, then retreated by 7.11% to 36690000.0 in 2025, then surged by 239.68% to 51249000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 51249000.0, 36690000.0, and 12421000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 51.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.25 Mn |
| Dec 31, 2025 | -36.69 Mn |
| Sep 30, 2025 | -12.42 Mn |
| Jun 30, 2025 | -31.13 Mn |
| Mar 31, 2025 | -37.57 Mn |
| Dec 31, 2024 | -34.26 Mn |
| Sep 30, 2024 | -37.11 Mn |
| Jun 30, 2024 | -65.13 Mn |
| Mar 31, 2024 | -43.85 Mn |
| Dec 31, 2023 | -43.40 Mn |
| Sep 30, 2023 | -51.66 Mn |
| Jun 30, 2023 | -44.29 Mn |
| Mar 31, 2023 | -39.68 Mn |
| Dec 31, 2022 | -46.05 Mn |
| Sep 30, 2022 | -54.79 Mn |
| Jun 30, 2022 | -41.70 Mn |
| Mar 31, 2022 | -39.49 Mn |
| Dec 31, 2021 | -105.16 Mn |
| Sep 30, 2021 | -22.70 Mn |
| Jun 30, 2021 | -50.52 Mn |
| Mar 31, 2021 | -50.19 Mn |
| Dec 31, 2020 | -72.30 Mn |
| Sep 30, 2020 | -38.46 Mn |
| Jun 30, 2020 | -33.66 Mn |
| Mar 31, 2020 | -29.58 Mn |
| Dec 31, 2019 | -111.88 Mn |
| Sep 30, 2019 | -16.46 Mn |
| Jun 30, 2019 | -14.87 Mn |
| Mar 31, 2019 | -24.84 Mn |
| Dec 31, 2018 | -23.62 Mn |
| Sep 30, 2018 | -40.04 Mn |
| Jun 30, 2018 | -34.29 Mn |
| Mar 31, 2018 | -30.51 Mn |
| Dec 31, 2017 | -16.99 Mn |
| Sep 30, 2017 | -7.89 Mn |
| Jun 30, 2017 | -14.66 Mn |
| Mar 31, 2017 | -15.39 Mn |
| Dec 31, 2016 | -14.31 Mn |
| Sep 30, 2016 | -14.17 Mn |
| Jun 30, 2016 | -12.79 Mn |
| Mar 31, 2016 | -20.83 Mn |
| Dec 31, 2015 | -18.85 Mn |
| Sep 30, 2015 | -20.17 Mn |
| Jun 30, 2015 | -16.90 Mn |
| Mar 31, 2015 | -18.89 Mn |
| Dec 31, 2014 | -21.10 Mn |
| Sep 30, 2014 | -18.07 Mn |
| Jun 30, 2014 | -18.15 Mn |
| Mar 31, 2014 | -16.35 Mn |
| Dec 31, 2013 | -13.92 Mn |
| Sep 30, 2013 | -14.02 Mn |
| Jun 30, 2013 | -13.75 Mn |
| Mar 31, 2013 | -10.60 Mn |
| Dec 31, 2012 | -7.89 Mn |
| Sep 30, 2012 | -13.44 Mn |
| Jun 30, 2012 | -8.69 Mn |
| Mar 31, 2012 | -8.55 Mn |
| Dec 31, 2011 | -10.37 Mn |
| Sep 30, 2011 | -6.68 Mn |
| Jun 30, 2011 | -5.46 Mn |
| Mar 31, 2011 | -6.73 Mn |
| Dec 31, 2010 | -8.85 Mn |
| Sep 30, 2010 | -7.74 Mn |
| Jun 30, 2010 | -8.02 Mn |